Immunology in the news
Immunology in the news
British Society for Immunology response to the Government lifting a ban on UK-sourced blood plasma being used in the manufacture of life-saving medicines, known as immunoglobulins.
BSI response to new pre-print study on the effect of the first dose of the Pfizer/BioNTech and the Oxford/AstraZeneca vaccines on preventing severe illness resulting in hospitalisation in Scotland.
British Society for Immunology response to data from Israel on the effectiveness of the Pfizer/BioNTech vaccine after one dose in healthcare workers.
British Society for Immunology response to new report from the Royal Society for Public Health on flu vaccination rates in London.
Press release on BSI report on immunity and COVID-19.
BSI response to pre-print from The Lancet on the dosing schedule for the AstraZeneca/Oxford COVID-19 vaccine
BSI response to Germany’s vaccine committee recommendation to only give the AstraZeneca/Oxford COVID-19 vaccine to people aged under 65.
Alopecia UK has joined Connect Immune Research, an initiative designed to bring about a critical change in the way autoimmune conditions are researched. The BSI is a supporting partner of this initiative, along founding members JDRF, the MS Society and Versus Arthritis.
This statement is aimed at people who either have a medical condition which means their immune system doesn’t function optimally or people who take medication that suppresses their immune system.
British Society for Immunology statement in response to the approval of the Moderna COVID-19 vaccine in the UK.
The British Society for Immunology has produced a statement that lays out our position on the announcements around change of dosing schedule for the two approved COVID-19 vaccines.
British Society for Immunology statement in response to news of approval of Oxford University/AstraZeneca COVID-19 vaccine for use in UK
British Society for Immunology response to reports of two allergic reactions following COVID-19 vaccination
British Society for Immunology response to COVID-19 vaccine rollout on NHS
British Society for Immunology response to The Lancet paper on interim phase 3 trial results for the University of Oxford/AstraZeneca COVID-19 vaccine